Roche Palo Alto, engages in the discovery, development, and marketing of medicines for inflammatory or viral diseases. The company provides medicines for the treatment for a range of diseases, including severe asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis. The company was formerly known as Syntex (U.S.A.) LLC and changed its name in 1994. The company was incorporated in 1960 and is based in Palo Alto, California. Roche Palo Alto, LLC operates as a subsidiary of Roche Holding AG.
Source (businessweek) {http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=8102245}